Tamoxifen
Tamoxifen is used for treating breast cancer that has spread to other sites of the body.
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.72 | $43.00 (0%) | 🛒 Add to cart |
| 90 | $0.67 | $64.50 $60.00 (7%) | 🛒 Add to cart |
| 120 | $0.63 | $86.00 $76.00 (12%) | 🛒 Add to cart |
| 180 | $0.61 | $129.00 $109.00 (16%) | 🛒 Add to cart |
| 270 | $0.59 | $193.50 $159.00 (18%) | 🛒 Add to cart |
| 360 | $0.58
Best per pill | $258.00 $209.00 (19%) | 🛒 Add to cart |
Synonyms
| |||
Similar products
More info:
Arimidex: Advanced Aromatase Inhibition for Breast Cancer Treatment
Arimidex (anastrozole) represents a significant advancement in endocrine therapy for hormone receptor-positive breast cancer in postmenopausal women. As a third-generation aromatase inhibitor, it specifically targets the aromatase enzyme system responsible for estrogen production. This medication has demonstrated superior efficacy compared to traditional anti-estrogen therapies in multiple clinical trials, establishing itself as a cornerstone in both adjuvant and metastatic treatment settings. The selective mechanism of action minimizes estrogen synthesis without affecting other steroid hormone pathways, offering a targeted approach to hormone-sensitive malignancies.
Aromasin: Advanced Estrogen Control for Breast Cancer Therapy
Aromasin (exemestane) is a potent, steroidal aromatase inactivator specifically formulated for the treatment of estrogen receptor-positive early and advanced breast cancer in postmenopausal women. As a third-generation aromatase inhibitor, it offers a targeted mechanism of action by irreversibly binding to the aromatase enzyme, leading to a significant and sustained reduction in circulating estrogen levels. This makes it a cornerstone in hormonal therapy, particularly following initial treatment with tamoxifen, where it has demonstrated superior efficacy in reducing recurrence risk and improving long-term outcomes.
Femara: Advanced Aromatase Inhibition for Breast Cancer Treatment
Femara (letrozole) is a potent, non-steroidal aromatase inhibitor indicated for the treatment of hormone receptor-positive early and advanced breast cancer in postmenopausal women. As a third-generation aromatase inhibitor, it represents a significant advancement in endocrine therapy by effectively suppressing estrogen production through targeted enzymatic inhibition. Its mechanism of action provides a sophisticated approach to hormone manipulation, offering superior estrogen suppression compared to earlier therapeutic options. Clinical evidence supports its use in both adjuvant and metastatic settings, establishing it as a cornerstone in the management of hormone-sensitive breast malignancies.
Nolvadex: Targeted Estrogen Blockade for Breast Cancer Management
Nolvadex (tamoxifen citrate) is a cornerstone selective estrogen receptor modulator (SERM) used in the hormonal therapy of breast cancer. It represents one of the most extensively studied and clinically validated oral endocrine treatments in oncology. By competitively antagonizing estrogen receptors in breast tissue, Nolvadex disrupts the hormone-dependent proliferation of malignant cells, offering a targeted mechanism of action. Its well-established efficacy profile and generally favorable tolerability have secured its position as a first-line and adjuvant therapeutic option for decades, benefiting both premenopausal and postmenopausal patients with hormone receptor-positive disease.
Abana: Natural Cardiovascular Support for Optimal Heart Health
Abana is a clinically studied, multi-herbal formulation designed to support cardiovascular wellness and maintain healthy cholesterol levels already within the normal range. This expert-formulated supplement combines time-tested Ayurvedic herbs with modern pharmacological understanding to provide a holistic approach to heart health. It functions by promoting healthy lipid metabolism, supporting arterial elasticity, and providing antioxidant protection against oxidative stress. For individuals seeking a natural adjunct to a heart-healthy lifestyle, Abana offers a scientifically grounded option backed by traditional use and contemporary research.
Accupril: Effective Blood Pressure Control for Cardiovascular Health
Accupril (quinapril hydrochloride) is an angiotensin-converting enzyme (ACE) inhibitor prescription medication specifically formulated for the management of hypertension and heart failure. As a frontline therapeutic agent, it works by inhibiting the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby promoting vasodilation and reducing peripheral arterial resistance. This mechanism of action makes it a cornerstone in cardiovascular risk reduction strategies, particularly for patients requiring comprehensive blood pressure management alongside other cardiovascular conditions.
Actigall: Effective Dissolution Therapy for Gallstones
Actigall (ursodiol) is a bile acid medication specifically formulated to dissolve certain types of gallstones in patients for whom surgery poses an unacceptable risk. It works by reducing the cholesterol saturation of bile, thereby promoting the gradual dissolution of radiolucent, non-calcified cholesterol stones in a functioning gallbladder. This oral therapy represents a non-surgical alternative for a carefully selected patient population, offering a targeted approach to managing symptomatic gallstone disease under expert medical supervision.
Actonel: Clinically Proven to Increase Bone Mineral Density
Actonel (risedronate sodium) is a bisphosphonate medication specifically formulated for the treatment and prevention of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. It works by inhibiting osteoclast-mediated bone resorption, thereby slowing bone loss, reducing the risk of fractures, and promoting a positive bone remodeling balance. This oral tablet is a cornerstone of pharmacological management for bone density conditions, offering a well-tolerated profile with proven long-term efficacy in maintaining skeletal integrity.
Aggrenox: Dual-Antiplatelet Protection Against Recurrent Stroke
Aggrenox is a prescription medication specifically formulated to reduce the risk of recurrent ischemic stroke in patients who have experienced a prior stroke or transient ischemic attack (TIA). It combines two active antiplatelet agents—aspirin and dipyridamole—in an extended-release formulation designed to work synergistically. This combination therapy targets distinct pathways of platelet aggregation, offering a comprehensive approach to secondary stroke prevention. By inhibiting clot formation through complementary mechanisms, Aggrenox provides a robust therapeutic option backed by clinical evidence demonstrating significant risk reduction compared to monotherapy approaches.